Sanofi's $2.56bn bispecific autoimmune deal with Earendil Labs is the second in recent history, and will bolster the French ...

Samsung Bioepis has started direct commercialisation of Byooviz, a biosimilar to Genentech’s Lucentis (ranibizumab), in ...

NICE has recommended Tysabri and biosimilar Tyruko as an option for patients with highly active relapsing-remitting multiple ...

Insilico Medicine has entered a multi-year R&D collaboration with Servier, worth up to $888m, to develop and discover new oncology therapies.

Valneva and the Serum Institute of India (SII) have ended a license agreement for chikungunya vaccine supply in Asia after ...

The approval marks the first new pharmacologic treatment in motion sickness in over four decades. The US Food and Drug ...

Johnson & Johnson (J&J) has completed its acquisition of Halda Therapeutics, a clinical-stage biotechnology company, for ...

In early December, the 2025 updates of China’s NRDL were finalised with a total of 114 drugs, including Western drugs and ...

Outlook Therapeutics has received the US FDA's CRL regarding the BLA resubmission for ONS-5010/LYTENAVA to treat wet AMD.

Maryland’s Prescription Drug Affordability Board (PDAB) serves as a bellwether for how other states may address high drug ...

Data indicating unequal treatment effects in women has prompted calls for more nuance in Alzheimer’s diagnosis and drug ...

Sanofi has agreed to acquire hepatitis B vaccine manufacturer Dynavax for an equity value of around $2.2bn, bolstering the ...